Brief: Hyloris Pharmaceuticals Says During H1 2023, Total Revenue, Other Income Increased To EUR 2,391 Thousand Versus EUR 1,229 Thousand In H1 2022
06/09/2023 21:04
Sept 6 (Reuters) - Hyloris Pharmaceuticals SA HYL.BR :
* MAINTAINS ITS STRONG CASH POSITION, WITH CURRENT CASH AND
CASH
EQUIVALENTS TOTALING EUR 39,159 THOUSAND ON 30 JUNE
* REALIZED A NET LOSS OF EUR 6,634 THOUSAND FOR SIX-MONTH
PERIOD
ENDING 30 JUNE 2023
* HYLORIS PHARMACEUTICALS-DURING FIRST SIX MONTHS OF 2023,
TOTAL
REVENUE, OTHER INCOME INCREASED TO EUR 2,391 THOUSAND VERSUS EUR
1,229 THOUSAND IN H1 2022
Source text for Eikon: ID:nGNE3lwcF3
Further company coverage: HYL.BR
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hyloris Pharmaceuticals SA
See all newsEurope Research Roundup: Akzo Nobel, MTU Aero Engines, Symrise
Brief: Hyloris Pharmaceuticals Says It Obtains Exclusive License Rights In Europe & Turkey From Arbormed For Its Wilson's Disease Therapy
Brief: Hyloris Announces Partnership With Rosemont Pharmaceuticals For Atomoxetine Oral Solution In The U.S.
Brief: Hyloris Announces Positive Study Results For Dofetilide IV
Brief: Hyloris Pharmaceuticals SA Says HY 2024 Revenues (Royalties And Milestones) Increased To EUR 4,2 Million